Skip to main content

2017 | OriginalPaper | Buchkapitel

13. Marketing Models for the Life Sciences Industry

verfasst von : Vardan Avagyan, Vardit Landsman, Stefan Stremersch

Erschienen in: Handbook of Marketing Decision Models

Verlag: Springer International Publishing

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

The life sciences industry forms the innovative producer side of therapies in the healthcare industry. The industry has several unique features and is an important part of the economy. The life sciences industry gives rise to interesting research questions, as well as enables new model development to support managerial decision making. The academic marketing literature has produced a sizeable array of decision-support tools for the life science marketers. In this chapter, we present to researchers and managers in the life sciences industry a broad overview of these analytical tools, categorized according to subject areas, and the key managerial insights that have been derived from them. We first present the typical models employed in the following modeling traditions: choice model, count model, learning model, modeling key opinion leaders, diffusion model, sales growth model, and launch model. We then discuss the findings on the role of marketing categorized according to the following decision areas: direct-to-physician promotion, direct-to-consumer advertising, pricing, and product usage adherence. We conclude with a number of areas that we think need more research.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
Zurück zum Zitat Albers, S., M. Mantrala, and S. Sridhar. 2010. Personal selling elasticities: A meta-analysis. Journal of Marketing Research 47 (5): 840–853.CrossRef Albers, S., M. Mantrala, and S. Sridhar. 2010. Personal selling elasticities: A meta-analysis. Journal of Marketing Research 47 (5): 840–853.CrossRef
Zurück zum Zitat Amaldoss, W., and C. He. 2009. Direct-to-consumer advertising of prescription drugs: A strategic analysis. Marketing Science 28 (3): 472–487.CrossRef Amaldoss, W., and C. He. 2009. Direct-to-consumer advertising of prescription drugs: A strategic analysis. Marketing Science 28 (3): 472–487.CrossRef
Zurück zum Zitat Anderson, S., F. Ciliberto, J. Liaukonyte, and R. Renault. 2016. Push-me, pull-you: Comparative advertising in the OTC analgesics industry. Working paper. Anderson, S., F. Ciliberto, J. Liaukonyte, and R. Renault. 2016. Push-me, pull-you: Comparative advertising in the OTC analgesics industry. Working paper.
Zurück zum Zitat Azoulay, P. 2002. Do pharmaceutical sales respond to scientific evidence? Journal of Economics and Management Strategy 11 (4): 551–594.CrossRef Azoulay, P. 2002. Do pharmaceutical sales respond to scientific evidence? Journal of Economics and Management Strategy 11 (4): 551–594.CrossRef
Zurück zum Zitat Bass, F. 1969. A new-product growth model for consumer durables. Management Science 15 (5): 215–227.CrossRef Bass, F. 1969. A new-product growth model for consumer durables. Management Science 15 (5): 215–227.CrossRef
Zurück zum Zitat Berndt, E., L. Bui, D. Reiley, and G. Urban. 1995. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 85 (2): 100–105. Berndt, E., L. Bui, D. Reiley, and G. Urban. 1995. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 85 (2): 100–105.
Zurück zum Zitat Bhatia, T., and L. Wang. 2011. Identifying physician peer-to-peer effects using patient movement data. International Journal of Marketing Research 28 (1): 51–61.CrossRef Bhatia, T., and L. Wang. 2011. Identifying physician peer-to-peer effects using patient movement data. International Journal of Marketing Research 28 (1): 51–61.CrossRef
Zurück zum Zitat Bhattacharya, J., and W. Vogt. 2003. A simple model of pharmaceutical price dynamics. Journal of Law and Economics 23 (2): 599–626.CrossRef Bhattacharya, J., and W. Vogt. 2003. A simple model of pharmaceutical price dynamics. Journal of Law and Economics 23 (2): 599–626.CrossRef
Zurück zum Zitat Bowman, D., C. Heilman, and P. Seetharaman. 2004. Determinants of product-use compliance behavior. Journal of Marketing Research 41 (3): 324–338.CrossRef Bowman, D., C. Heilman, and P. Seetharaman. 2004. Determinants of product-use compliance behavior. Journal of Marketing Research 41 (3): 324–338.CrossRef
Zurück zum Zitat Brekke, K., and M. Kuhn. 2006. Direct to consumer advertising in pharmaceutical markets. Journal of Health Economics 25 (1): 102–130.CrossRef Brekke, K., and M. Kuhn. 2006. Direct to consumer advertising in pharmaceutical markets. Journal of Health Economics 25 (1): 102–130.CrossRef
Zurück zum Zitat Brekke, K., T. Holmas, and O. Straume. 2015. Price regulation and parallel imports of pharmaceuticals. Journal of Public Economics 129: 92–105.CrossRef Brekke, K., T. Holmas, and O. Straume. 2015. Price regulation and parallel imports of pharmaceuticals. Journal of Public Economics 129: 92–105.CrossRef
Zurück zum Zitat Calabro, S. 2003. In DTC-free Europe, just as many patients ask for brand drugs. Medical Marketing and Media 38 (11): 30. Calabro, S. 2003. In DTC-free Europe, just as many patients ask for brand drugs. Medical Marketing and Media 38 (11): 30.
Zurück zum Zitat Calfee, J., C. Winston, and R. Stempski. 2002. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. Journal of Law Economics 45 (S2): 673–690.CrossRef Calfee, J., C. Winston, and R. Stempski. 2002. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. Journal of Law Economics 45 (S2): 673–690.CrossRef
Zurück zum Zitat Camacho, N., M. de Jong, and S. Stremersch. 2014. The effect of customer empowerment on adherence to expert advice. International Journal of Research in Marketing 31 (3): 293–308.CrossRef Camacho, N., M. de Jong, and S. Stremersch. 2014. The effect of customer empowerment on adherence to expert advice. International Journal of Research in Marketing 31 (3): 293–308.CrossRef
Zurück zum Zitat Camacho, N., V. Landsman, and S. Stremersch. 2010. The Connected Patient, in The Connected Customer: The Changing Nature of Consumer and Business Markets, ed. Stefan Wuyts, Marnik G. Dekimpe, Els Gijsbrechts, and F.G.M. Pieters, Hampshire, UK: Routledge Academic. Camacho, N., V. Landsman, and S. Stremersch. 2010. The Connected Patient, in The Connected Customer: The Changing Nature of Consumer and Business Markets, ed. Stefan Wuyts, Marnik G. Dekimpe, Els Gijsbrechts, and F.G.M. Pieters, Hampshire, UK: Routledge Academic.
Zurück zum Zitat Camacho, N., B. Donkers, and S. Stremersch. 2011. Predictably non-Bayesian: Quantifying salience effects in physician learning about drug quality. Marketing Science 30 (2): 305–320.CrossRef Camacho, N., B. Donkers, and S. Stremersch. 2011. Predictably non-Bayesian: Quantifying salience effects in physician learning about drug quality. Marketing Science 30 (2): 305–320.CrossRef
Zurück zum Zitat Campbell, E., G. Pham-Kanter, C. Vogeli, and L. Iezzoni. 2013. Physician acquiescence to patient demands for brand-name drugs: Results of national survey of physicians. JAMA Internal Medicine 173 (3): 237–239.CrossRef Campbell, E., G. Pham-Kanter, C. Vogeli, and L. Iezzoni. 2013. Physician acquiescence to patient demands for brand-name drugs: Results of national survey of physicians. JAMA Internal Medicine 173 (3): 237–239.CrossRef
Zurück zum Zitat Caves, R., M. Whinston, M. Hurwitz, A. Pakes, and P. Temin. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry: Comments and discussion. Brookings Papers Economic Activity 12 (1): 1–66. Caves, R., M. Whinston, M. Hurwitz, A. Pakes, and P. Temin. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry: Comments and discussion. Brookings Papers Economic Activity 12 (1): 1–66.
Zurück zum Zitat Chan, T., C. Narasimhan, and Y. Xie. 2013. Treatment effectiveness and side effects: A model of physician learning. Management Science 59 (6): 1309–1325.CrossRef Chan, T., C. Narasimhan, and Y. Xie. 2013. Treatment effectiveness and side effects: A model of physician learning. Management Science 59 (6): 1309–1325.CrossRef
Zurück zum Zitat Ching, A., and M. Ishihara. 2010. The effects of detailing on prescribing decisions under quality uncertainty. Quantitative Marketing and Economics 8 (2): 123–165.CrossRef Ching, A., and M. Ishihara. 2010. The effects of detailing on prescribing decisions under quality uncertainty. Quantitative Marketing and Economics 8 (2): 123–165.CrossRef
Zurück zum Zitat Chintagunta, P., and R. Desiraju. 2005. Strategic pricing and detailing behavior in international markets. Marketing Science 24 (1): 67–80.CrossRef Chintagunta, P., and R. Desiraju. 2005. Strategic pricing and detailing behavior in international markets. Marketing Science 24 (1): 67–80.CrossRef
Zurück zum Zitat Chintagunta, P., R. Goettler, and M. Kim. 2012. New drug diffusion when forward-looking physicians learn from patient feedback and detailing. Journal Marketing Research 49 (6): 807–821.CrossRef Chintagunta, P., R. Goettler, and M. Kim. 2012. New drug diffusion when forward-looking physicians learn from patient feedback and detailing. Journal Marketing Research 49 (6): 807–821.CrossRef
Zurück zum Zitat Chintagunta, P.K., R. Jiang, and G.Z. Jin. 2009. Information, learning, and drug diffusion: The case of cox-2 inhibitors. Quantitative Marketing and Economics 7 (4): 399–443.CrossRef Chintagunta, P.K., R. Jiang, and G.Z. Jin. 2009. Information, learning, and drug diffusion: The case of cox-2 inhibitors. Quantitative Marketing and Economics 7 (4): 399–443.CrossRef
Zurück zum Zitat Cockburn, I., J. Lanjouw, and M. Schankerman. 2014. Patents and global diffusion of new drugs. NBER Working Paper 20492. Cockburn, I., J. Lanjouw, and M. Schankerman. 2014. Patents and global diffusion of new drugs. NBER Working Paper 20492.
Zurück zum Zitat Coleman, J.S., E. Katz, and H. Menzel. 1966. Medical Innovation: A diffusion study. Indianapolis: Bobbs-Merrill. Coleman, J.S., E. Katz, and H. Menzel. 1966. Medical Innovation: A diffusion study. Indianapolis: Bobbs-Merrill.
Zurück zum Zitat Coscelli, A., and M. Shum. 2004. An empirical model of learning and patient spillover in new drug entry. Journal of Econometrics 122 (2): 213–246.CrossRef Coscelli, A., and M. Shum. 2004. An empirical model of learning and patient spillover in new drug entry. Journal of Econometrics 122 (2): 213–246.CrossRef
Zurück zum Zitat Danzon, P., R. Wang, and L. Wang. 2005. The impact of price regulation on the launch delay of new drugs: Evidence from twenty-five major markets in the 1990s. Health Economics 14 (3): 269–292.CrossRef Danzon, P., R. Wang, and L. Wang. 2005. The impact of price regulation on the launch delay of new drugs: Evidence from twenty-five major markets in the 1990s. Health Economics 14 (3): 269–292.CrossRef
Zurück zum Zitat Danzon, P., A. Towse, and J. Mestre-Ferrandiz. 2015. Value-based differential pricing: Efficient prices for drugs in a global context. Health Economics 24 (3): 294–301.CrossRef Danzon, P., A. Towse, and J. Mestre-Ferrandiz. 2015. Value-based differential pricing: Efficient prices for drugs in a global context. Health Economics 24 (3): 294–301.CrossRef
Zurück zum Zitat Datta, A., and D. Dave. 2013. Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence. NBER Working Paper 19592. Datta, A., and D. Dave. 2013. Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence. NBER Working Paper 19592.
Zurück zum Zitat Dellande, S., M. Gilly, and J. Graham. 2004. Gaining compliance and losing weight: The role of the service provider in health care services. Journal of Marketing 68 (3): 78–91.CrossRef Dellande, S., M. Gilly, and J. Graham. 2004. Gaining compliance and losing weight: The role of the service provider in health care services. Journal of Marketing 68 (3): 78–91.CrossRef
Zurück zum Zitat Desiraju, R., H. Nair, and P. Chintagunta. 2004. Diffusion of new pharmaceutical drugs in developing and developed nations. International Journal of Research in Marketing 21 (4): 341–357.CrossRef Desiraju, R., H. Nair, and P. Chintagunta. 2004. Diffusion of new pharmaceutical drugs in developing and developed nations. International Journal of Research in Marketing 21 (4): 341–357.CrossRef
Zurück zum Zitat Dong, X., P. Chintagunta, and P. Manchanda. 2011. A new multivariate count data model to study multi-category physician prescription behavior. Quantitative Marketing and Economics 9 (3): 301–337.CrossRef Dong, X., P. Chintagunta, and P. Manchanda. 2011. A new multivariate count data model to study multi-category physician prescription behavior. Quantitative Marketing and Economics 9 (3): 301–337.CrossRef
Zurück zum Zitat Donohue, J., E. Berndt, M. Rosenthal, A. Epstein, and R. Frank. 2004. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 42 (12): 1176–1185.CrossRef Donohue, J., E. Berndt, M. Rosenthal, A. Epstein, and R. Frank. 2004. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 42 (12): 1176–1185.CrossRef
Zurück zum Zitat Duso, T., A. Herr, and M. Suppliet. 2014. The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics. Health Economics 23 (9): 1036–1057.CrossRef Duso, T., A. Herr, and M. Suppliet. 2014. The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics. Health Economics 23 (9): 1036–1057.CrossRef
Zurück zum Zitat EFPIA. 2015. The pharmaceutical industry in figures. Brussels, Belgium: European Federation of Pharmaceutical Industries and Associations. EFPIA. 2015. The pharmaceutical industry in figures. Brussels, Belgium: European Federation of Pharmaceutical Industries and Associations.
Zurück zum Zitat Ekelund, M., and B. Persson. 2003. Pharmaceutical pricing in a regulated market. The Review of Economics and Statistics 85 (2): 298–306.CrossRef Ekelund, M., and B. Persson. 2003. Pharmaceutical pricing in a regulated market. The Review of Economics and Statistics 85 (2): 298–306.CrossRef
Zurück zum Zitat Fang, E., J. Lee, and Z. Yang. 2015. The timing of codevelopment alliances in new product development processes: Returns for upstream and downstream partners. Journal of Marketing 79 (1): 64–82.CrossRef Fang, E., J. Lee, and Z. Yang. 2015. The timing of codevelopment alliances in new product development processes: Returns for upstream and downstream partners. Journal of Marketing 79 (1): 64–82.CrossRef
Zurück zum Zitat Ferguson, J., R. Discenza, and J. Miller. 1987. Increasing the odds of patient compliance through prescription warning labels. Journal of Health Care Marketing 7 (1): 37–46. Ferguson, J., R. Discenza, and J. Miller. 1987. Increasing the odds of patient compliance through prescription warning labels. Journal of Health Care Marketing 7 (1): 37–46.
Zurück zum Zitat Fischer, M., and S. Albers. 2010. Patient- or physician-oriented marketing: What drives primary demand for prescription drugs? Journal of Marketing Research 47 (1): 103–121.CrossRef Fischer, M., and S. Albers. 2010. Patient- or physician-oriented marketing: What drives primary demand for prescription drugs? Journal of Marketing Research 47 (1): 103–121.CrossRef
Zurück zum Zitat Frank, R., and D. Salkever. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6 (1): 75–90.CrossRef Frank, R., and D. Salkever. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6 (1): 75–90.CrossRef
Zurück zum Zitat Ganslandt, M., and K. Maskus. 2004. Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics 23 (5): 1035–1057.CrossRef Ganslandt, M., and K. Maskus. 2004. Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics 23 (5): 1035–1057.CrossRef
Zurück zum Zitat Goldenberg, J., B. Libai, and E. Muller. 2002. Riding the saddle: How cross-market communications can create a major slump in sales. Journal of Marketing 66 (2): 1–16.CrossRef Goldenberg, J., B. Libai, and E. Muller. 2002. Riding the saddle: How cross-market communications can create a major slump in sales. Journal of Marketing 66 (2): 1–16.CrossRef
Zurück zum Zitat Gonzalez, J., C. Sismeiro, and S. Dutta. 2008. Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. International Journal of Research in Marketing 25 (4): 247–260.CrossRef Gonzalez, J., C. Sismeiro, and S. Dutta. 2008. Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules. International Journal of Research in Marketing 25 (4): 247–260.CrossRef
Zurück zum Zitat Gönül, F., F. Carter, E. Petrova, and K. Srinivasan. 2001. Promotion of prescription drugs and its impact on physicians’ choice behavior. Journal of Marketing 65 (3): 79–90.CrossRef Gönül, F., F. Carter, E. Petrova, and K. Srinivasan. 2001. Promotion of prescription drugs and its impact on physicians’ choice behavior. Journal of Marketing 65 (3): 79–90.CrossRef
Zurück zum Zitat Grabowski, H., and J. Vernon. 1992. Brand loyalty, entry, and price-competition in pharmaceuticals after the 1984 drug-act. Journal of Law and Economics 35 (2): 331–350.CrossRef Grabowski, H., and J. Vernon. 1992. Brand loyalty, entry, and price-competition in pharmaceuticals after the 1984 drug-act. Journal of Law and Economics 35 (2): 331–350.CrossRef
Zurück zum Zitat Grewal, R., A. Chakravarty, M. Ding, and J. Liechty. 2008. Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector. International Journal of Research in Marketing 25 (4): 261–272.CrossRef Grewal, R., A. Chakravarty, M. Ding, and J. Liechty. 2008. Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector. International Journal of Research in Marketing 25 (4): 261–272.CrossRef
Zurück zum Zitat Hahn, M., S. Park, L. Krishnamurthi, and A.A. Zoltners. 1994. Analysis of new product diffusion using a 4-segment trial-repeat model. Marketing Science 13 (3): 224–247.CrossRef Hahn, M., S. Park, L. Krishnamurthi, and A.A. Zoltners. 1994. Analysis of new product diffusion using a 4-segment trial-repeat model. Marketing Science 13 (3): 224–247.CrossRef
Zurück zum Zitat Hellerstein, J. 1998. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 29 (1): 108–136.CrossRef Hellerstein, J. 1998. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 29 (1): 108–136.CrossRef
Zurück zum Zitat Iizuka, T., and G. Jin. 2005. The effect of prescription drug advertising on doctor visits. Journal of Economic Management Strategy 14 (3): 701–727.CrossRef Iizuka, T., and G. Jin. 2005. The effect of prescription drug advertising on doctor visits. Journal of Economic Management Strategy 14 (3): 701–727.CrossRef
Zurück zum Zitat Iyengar, R., C. Van den Bulte, and T. Valente. 2011. Opinion leadership and social contagion in new product diffusion. Marketing Science 30 (2): 195–112.CrossRef Iyengar, R., C. Van den Bulte, and T. Valente. 2011. Opinion leadership and social contagion in new product diffusion. Marketing Science 30 (2): 195–112.CrossRef
Zurück zum Zitat Iyengar, R., C. Van den Bulte, and J. Lee. 2015. Social contagion in new product trial and repeat. Marketing Science 34 (3): 408–429.CrossRef Iyengar, R., C. Van den Bulte, and J. Lee. 2015. Social contagion in new product trial and repeat. Marketing Science 34 (3): 408–429.CrossRef
Zurück zum Zitat Jacobzone, S. (2000) Pharmaceutical policies in OECD countries: Reconciling social and industrial goals. OECD Labour Market and Social Policy—Occasional papers 40. Paris, France: OECD. Jacobzone, S. (2000) Pharmaceutical policies in OECD countries: Reconciling social and industrial goals. OECD Labour Market and Social Policy—Occasional papers 40. Paris, France: OECD.
Zurück zum Zitat Janakiraman, R., S. Dutta, C. Sismeiro, and P. Stern. 2008. Physicians’ persistence and its implications for their response to promotion of prescription drugs. Management Science 54 (6): 1080–1093.CrossRef Janakiraman, R., S. Dutta, C. Sismeiro, and P. Stern. 2008. Physicians’ persistence and its implications for their response to promotion of prescription drugs. Management Science 54 (6): 1080–1093.CrossRef
Zurück zum Zitat Janakiraman, R., C. Sismeiro, and S. Dutta. 2009. Perception spillovers across competing brands: A disaggregate model of how and when. Journal of Marketing Research 46 (4): 467–481.CrossRef Janakiraman, R., C. Sismeiro, and S. Dutta. 2009. Perception spillovers across competing brands: A disaggregate model of how and when. Journal of Marketing Research 46 (4): 467–481.CrossRef
Zurück zum Zitat Kahn, B., and M. Luce. 2003. Understanding high-stakes consumer decisions: Mammography adherence following false-alarm test results. Marketing Science 22 (3): 393–410.CrossRef Kahn, B., and M. Luce. 2003. Understanding high-stakes consumer decisions: Mammography adherence following false-alarm test results. Marketing Science 22 (3): 393–410.CrossRef
Zurück zum Zitat Kalra, A., S. Li, and W. Zhang. 2011. Understanding responses to contradictory information about products. Marketing Science 30 (6): 1098–1114.CrossRef Kalra, A., S. Li, and W. Zhang. 2011. Understanding responses to contradictory information about products. Marketing Science 30 (6): 1098–1114.CrossRef
Zurück zum Zitat Kappe, E., and S. Stremersch. 2016. Drug detailing and doctors’ prescription decisions: The role of information content. Marketing Science, forthcoming. Kappe, E., and S. Stremersch. 2016. Drug detailing and doctors’ prescription decisions: The role of information content. Marketing Science, forthcoming.
Zurück zum Zitat Kolsarici, C., and D. Vakratsas. 2010. Category- versus brand-level advertising messages in a highly regulated environment. Journal of Marketing Research 47 (6): 1078–1089.CrossRef Kolsarici, C., and D. Vakratsas. 2010. Category- versus brand-level advertising messages in a highly regulated environment. Journal of Marketing Research 47 (6): 1078–1089.CrossRef
Zurück zum Zitat Kravitz, R., R. Bell, R. Azari, E. Krupat, S. Kelly-Reif, and D. Thom. 2002. Request fulfillment in office practice: Antecedents and relationship to outcomes. Medical Care 40 (1): 38–51.CrossRef Kravitz, R., R. Bell, R. Azari, E. Krupat, S. Kelly-Reif, and D. Thom. 2002. Request fulfillment in office practice: Antecedents and relationship to outcomes. Medical Care 40 (1): 38–51.CrossRef
Zurück zum Zitat Kremer, S., T. Bijmolt, P. Leeflang, and J. Wieringa. 2008. Generalizations on the Effectiveness of pharmaceutical promotional expenditures. International Journal of Research in Marketing 25 (4): 234–246.CrossRef Kremer, S., T. Bijmolt, P. Leeflang, and J. Wieringa. 2008. Generalizations on the Effectiveness of pharmaceutical promotional expenditures. International Journal of Research in Marketing 25 (4): 234–246.CrossRef
Zurück zum Zitat Kyle, M. 2006. The role of firm characteristics in pharmaceutical product launches. The Rand Journal of Economics 73 (3): 602–618.CrossRef Kyle, M. 2006. The role of firm characteristics in pharmaceutical product launches. The Rand Journal of Economics 73 (3): 602–618.CrossRef
Zurück zum Zitat Kyle, M. 2007. Pharmaceutical price controls and entry strategies. The Review of Economics and Statistics 89 (1): 88–99.CrossRef Kyle, M. 2007. Pharmaceutical price controls and entry strategies. The Review of Economics and Statistics 89 (1): 88–99.CrossRef
Zurück zum Zitat Kyle, M., and Y. Qian. 2014. Intellectual property rights and access to innovation: Evidence from TRIPS, NBER Working Paper 20799. Kyle, M., and Y. Qian. 2014. Intellectual property rights and access to innovation: Evidence from TRIPS, NBER Working Paper 20799.
Zurück zum Zitat Lamiraud, K., and P.-Y. Geoffard. 2007. Therapeutic non-adherence: A rational behavior revealing patient preferences? Health Economics 16 (11): 1185–1204.CrossRef Lamiraud, K., and P.-Y. Geoffard. 2007. Therapeutic non-adherence: A rational behavior revealing patient preferences? Health Economics 16 (11): 1185–1204.CrossRef
Zurück zum Zitat Lanjouw, J. 2005. Patents, price controls and access to new drugs: How policy affects global market entry. NBER, Cambridge, MA: NBER Working paper 11321. Lanjouw, J. 2005. Patents, price controls and access to new drugs: How policy affects global market entry. NBER, Cambridge, MA: NBER Working paper 11321.
Zurück zum Zitat Law, M., S. Majumdar, and S. Soumerai. 2008. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: Controlled longitudinal study. British Medical Journal 337: a1055.CrossRef Law, M., S. Majumdar, and S. Soumerai. 2008. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: Controlled longitudinal study. British Medical Journal 337: a1055.CrossRef
Zurück zum Zitat Lien, H.-M., M. Lu, C.-T. Ma, and T. McGuire. 2010. Progress and compliance in alcohol abuse treatment. Journal of Health Economics 29 (2): 213–225.CrossRef Lien, H.-M., M. Lu, C.-T. Ma, and T. McGuire. 2010. Progress and compliance in alcohol abuse treatment. Journal of Health Economics 29 (2): 213–225.CrossRef
Zurück zum Zitat Ling, D., E. Berndt, and M. Kyle. 2002. Deregulating direct-to-consumer marketing of prescription drugs: Effects on prescription and over-the-counter product sales. Journal of Law Economics 45 (2): 691–723.CrossRef Ling, D., E. Berndt, and M. Kyle. 2002. Deregulating direct-to-consumer marketing of prescription drugs: Effects on prescription and over-the-counter product sales. Journal of Law Economics 45 (2): 691–723.CrossRef
Zurück zum Zitat Liu, Q., and S. Gupta. 2011. The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: Empirical findings and public policy implications. International Journal of Research in Marketing 28 (3): 205–217.CrossRef Liu, Q., and S. Gupta. 2011. The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: Empirical findings and public policy implications. International Journal of Research in Marketing 28 (3): 205–217.CrossRef
Zurück zum Zitat Liu, Q., S. Gupta, S. Venkataraman, and H. Liu. 2015. An empirical model of drug detailing: Dynamic competition and policy implications. Management Science, forthcoming. Liu, Q., S. Gupta, S. Venkataraman, and H. Liu. 2015. An empirical model of drug detailing: Dynamic competition and policy implications. Management Science, forthcoming.
Zurück zum Zitat Lu, Z., and W. Comanor. 1998. Strategic pricing of new pharmaceuticals. The Review of Economics and Statistics 80 (1): 108–118.CrossRef Lu, Z., and W. Comanor. 1998. Strategic pricing of new pharmaceuticals. The Review of Economics and Statistics 80 (1): 108–118.CrossRef
Zurück zum Zitat Lundin, D. 2000. Moral hazard in physician prescription behaviour. Journal of Health Economics 19 (5): 639–662.CrossRef Lundin, D. 2000. Moral hazard in physician prescription behaviour. Journal of Health Economics 19 (5): 639–662.CrossRef
Zurück zum Zitat Manchanda, P., and P. Chintagunta. 2004. Responsiveness of prescription behavior to salesforce effort: An individual level analysis. Marketing Letters 25 (2–3): 129–145.CrossRef Manchanda, P., and P. Chintagunta. 2004. Responsiveness of prescription behavior to salesforce effort: An individual level analysis. Marketing Letters 25 (2–3): 129–145.CrossRef
Zurück zum Zitat Manchanda, P., P. Rossi, and P. Chintagunta. 2004. Response modeling with nonrandom marketing-mix variables. Journal of Marketing Research 41 (4): 467–478.CrossRef Manchanda, P., P. Rossi, and P. Chintagunta. 2004. Response modeling with nonrandom marketing-mix variables. Journal of Marketing Research 41 (4): 467–478.CrossRef
Zurück zum Zitat Manchanda, P., Y. Xie, and N. Youn. 2008. The role of targeted communication and contagion in new product adoption. Marketing Science 27 (6): 961–976.CrossRef Manchanda, P., Y. Xie, and N. Youn. 2008. The role of targeted communication and contagion in new product adoption. Marketing Science 27 (6): 961–976.CrossRef
Zurück zum Zitat Mintzes, B., M. Barer, R. Kravitz, B. Bassett, J. Lexchin, A. Kazanjian, R. Evans, R. Pan, and S. Marion. 2003. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal 169 (5): 405–412. Mintzes, B., M. Barer, R. Kravitz, B. Bassett, J. Lexchin, A. Kazanjian, R. Evans, R. Pan, and S. Marion. 2003. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal 169 (5): 405–412.
Zurück zum Zitat Mizik, N., and R. Jacobson. 2004. Are physicians easy marks? Quantifying the effects of detailing and sampling on new prescriptions. Management Science 50 (12): 1704–1715.CrossRef Mizik, N., and R. Jacobson. 2004. Are physicians easy marks? Quantifying the effects of detailing and sampling on new prescriptions. Management Science 50 (12): 1704–1715.CrossRef
Zurück zum Zitat Montgomery, D., and A. Silk. 1972. Estimating dynamic effects of market communications expenditures. Management Science 18 (10): B485–B501.CrossRef Montgomery, D., and A. Silk. 1972. Estimating dynamic effects of market communications expenditures. Management Science 18 (10): B485–B501.CrossRef
Zurück zum Zitat Montoya, R., O. Netzer, and K. Jedidi. 2010. Dynamic allocation of pharmaceutical detailing and sampling. Marketing Science 29 (5): 909–924.CrossRef Montoya, R., O. Netzer, and K. Jedidi. 2010. Dynamic allocation of pharmaceutical detailing and sampling. Marketing Science 29 (5): 909–924.CrossRef
Zurück zum Zitat Nair, H., P. Manchanda, and T. Bhatia. 2010. Asymmetric social interactions in physician prescription behavior: The role of opinion leaders. Journal of Marketing Research 47 (5): 883–895.CrossRef Nair, H., P. Manchanda, and T. Bhatia. 2010. Asymmetric social interactions in physician prescription behavior: The role of opinion leaders. Journal of Marketing Research 47 (5): 883–895.CrossRef
Zurück zum Zitat Narayanan, S., R. Desiraju, and P. Chintagunta. 2004. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. Journal of Marketing 68 (4): 90–105.CrossRef Narayanan, S., R. Desiraju, and P. Chintagunta. 2004. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. Journal of Marketing 68 (4): 90–105.CrossRef
Zurück zum Zitat Narayanan, S., and P. Manchanda. 2009. Heterogeneous learning and the targeting of marketing communication for new products. Marketing Science 28 (3): 424–441.CrossRef Narayanan, S., and P. Manchanda. 2009. Heterogeneous learning and the targeting of marketing communication for new products. Marketing Science 28 (3): 424–441.CrossRef
Zurück zum Zitat Narayanan, S., P. Manchanda, and P. Chintagunta. 2005. Temporal differences in the role of marketing communication in new product categories. Journal of Marketing Research 42 (3): 278–290.CrossRef Narayanan, S., P. Manchanda, and P. Chintagunta. 2005. Temporal differences in the role of marketing communication in new product categories. Journal of Marketing Research 42 (3): 278–290.CrossRef
Zurück zum Zitat Osinga, E., P. Leeflang, and J. Wieringa. 2010. Early marketing matters: A time-varying parameter approach to persistence modeling. Journal of Marketing Research 47 (1): 173–185.CrossRef Osinga, E., P. Leeflang, and J. Wieringa. 2010. Early marketing matters: A time-varying parameter approach to persistence modeling. Journal of Marketing Research 47 (1): 173–185.CrossRef
Zurück zum Zitat Osinga, E., P. Leeflang, S. Srinivasan, and J. Wieringa. 2011. Why do firms invest in consumer advertising with limited sales response? shareholder perspective. Journal of Marketing 75 (1): 109–124.CrossRef Osinga, E., P. Leeflang, S. Srinivasan, and J. Wieringa. 2011. Why do firms invest in consumer advertising with limited sales response? shareholder perspective. Journal of Marketing 75 (1): 109–124.CrossRef
Zurück zum Zitat Paruchuri, S., A. Nerkar, and D.C. Hambrick. 2006. Acquisition integration and productivity losses in the technical core: Disruption of inventors in acquired companies. Organization Science 17 (5): 545–562.CrossRef Paruchuri, S., A. Nerkar, and D.C. Hambrick. 2006. Acquisition integration and productivity losses in the technical core: Disruption of inventors in acquired companies. Organization Science 17 (5): 545–562.CrossRef
Zurück zum Zitat Parsons, L., and P. Vanden Abeele. 1981. Analysis of sales call effectiveness. Journal of Marketing Research 18 (1): 107–113.CrossRef Parsons, L., and P. Vanden Abeele. 1981. Analysis of sales call effectiveness. Journal of Marketing Research 18 (1): 107–113.CrossRef
Zurück zum Zitat Paterniti, D., T. Fancher, C. Cipri, S. Timmermans, J. Heritage, and R. Kravitz. 2010. Getting to “no”: Strategies primary care physicians use to deny patient requests. Archives of Internal Medicine 170 (4): 381–388.CrossRef Paterniti, D., T. Fancher, C. Cipri, S. Timmermans, J. Heritage, and R. Kravitz. 2010. Getting to “no”: Strategies primary care physicians use to deny patient requests. Archives of Internal Medicine 170 (4): 381–388.CrossRef
Zurück zum Zitat PhRMA. 2015a. Pharmaceutical industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America. PhRMA. 2015a. Pharmaceutical industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America.
Zurück zum Zitat PhRMA. 2015b. 2015 Profile Biopharmaceutical Research Industry. PhRMA. 2015b. 2015 Profile Biopharmaceutical Research Industry.
Zurück zum Zitat Prabhu, J.C., R.K. Chandy, and M.E. Ellis. 2005. The Impact of acquisitions on innovation: Poison pill, placebo, or tonic? Journal of Marketing 69 (1): 114–130.CrossRef Prabhu, J.C., R.K. Chandy, and M.E. Ellis. 2005. The Impact of acquisitions on innovation: Poison pill, placebo, or tonic? Journal of Marketing 69 (1): 114–130.CrossRef
Zurück zum Zitat Prigge, J.-K., B. Dietz, C. Homburg, W. Hoyer, and J. Burton. 2015. Patient empowerment: A cross-disease exploration of antecedents and consequences. International Journal of Research in Marketing 32 (4): 375–386.CrossRef Prigge, J.-K., B. Dietz, C. Homburg, W. Hoyer, and J. Burton. 2015. Patient empowerment: A cross-disease exploration of antecedents and consequences. International Journal of Research in Marketing 32 (4): 375–386.CrossRef
Zurück zum Zitat Rao, A., and M. Yamada. 1988. Forecasting with a repeat purchase diffusion model. Management Science 34 (6): 734–752.CrossRef Rao, A., and M. Yamada. 1988. Forecasting with a repeat purchase diffusion model. Management Science 34 (6): 734–752.CrossRef
Zurück zum Zitat Rizzo, J. 1999. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Journal of Law and Economics 42 (1): 89–116.CrossRef Rizzo, J. 1999. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Journal of Law and Economics 42 (1): 89–116.CrossRef
Zurück zum Zitat Rosenthal, M.B., E.R. Berndt, J.M. Donohue, A.M. Epstein, and R.G. Frank. 2003. Demand effects of recent changes in prescription drug promotion. Frontiers in Health Policy Research 6 (1): 1–26. Rosenthal, M.B., E.R. Berndt, J.M. Donohue, A.M. Epstein, and R.G. Frank. 2003. Demand effects of recent changes in prescription drug promotion. Frontiers in Health Policy Research 6 (1): 1–26.
Zurück zum Zitat Schwartz, J., M. Luce, and D. Ariely. 2011. Are consumers too trusting? The effects of relationships with expert advisers. Journal of Marketing Research 48 (Special Issue): S163–S174. Schwartz, J., M. Luce, and D. Ariely. 2011. Are consumers too trusting? The effects of relationships with expert advisers. Journal of Marketing Research 48 (Special Issue): S163–S174.
Zurück zum Zitat Scott, A., and A. Shiell. 1997. Do fee descriptors influence treatment choices in general practice? A multilevel discrete choice model. Journal of Health Economics 16 (3): 323–342.CrossRef Scott, A., and A. Shiell. 1997. Do fee descriptors influence treatment choices in general practice? A multilevel discrete choice model. Journal of Health Economics 16 (3): 323–342.CrossRef
Zurück zum Zitat Shah, M., J. Bentley, and D. McCaffrey III. 2006. Evaluations of care by adults following a denial of an advertisement-related prescription drug request: The role of expectations, symptom severity, and physician communication style. Social Science and Medicine 62 (4): 888–899.CrossRef Shah, M., J. Bentley, and D. McCaffrey III. 2006. Evaluations of care by adults following a denial of an advertisement-related prescription drug request: The role of expectations, symptom severity, and physician communication style. Social Science and Medicine 62 (4): 888–899.CrossRef
Zurück zum Zitat Shankar, V., G. Carpenter, and L. Krishnamurthi. 1998. Late mover advantage: How innovative late entrants outsell pioneers. Journal of Marketing Research 35 (1): 54–70.CrossRef Shankar, V., G. Carpenter, and L. Krishnamurthi. 1998. Late mover advantage: How innovative late entrants outsell pioneers. Journal of Marketing Research 35 (1): 54–70.CrossRef
Zurück zum Zitat Shankar, V., G. Carpenter, and L. Krishnamurthi. 1999. The advantages of entry in the growth stage of the product life cycle: An empirical analysis. Journal of Marketing Research 36 (2): 269–276.CrossRef Shankar, V., G. Carpenter, and L. Krishnamurthi. 1999. The advantages of entry in the growth stage of the product life cycle: An empirical analysis. Journal of Marketing Research 36 (2): 269–276.CrossRef
Zurück zum Zitat Sridhar, S., M. Mantrala, and S. Albers. 2014. Pharmaceutical detailing elasticities: A meta-analysis. In Innovation and marketing in the pharmaceutical industry: Emerging practices, research, and policies, ed. M. Ding, J. Eliashberg, and S. Stremersch. New York: Springer. Sridhar, S., M. Mantrala, and S. Albers. 2014. Pharmaceutical detailing elasticities: A meta-analysis. In Innovation and marketing in the pharmaceutical industry: Emerging practices, research, and policies, ed. M. Ding, J. Eliashberg, and S. Stremersch. New York: Springer.
Zurück zum Zitat Strang, D., and N.B. Tuma. 1993. Spatial and temporal heterogeneity in diffusion. American Journal of Sociology 99 (3): 614–639.CrossRef Strang, D., and N.B. Tuma. 1993. Spatial and temporal heterogeneity in diffusion. American Journal of Sociology 99 (3): 614–639.CrossRef
Zurück zum Zitat Stremersch, S. 2008. Health and marketing: The emergence of a new field of research. International Journal of Research in Marketing 25 (4): 229–233.CrossRef Stremersch, S. 2008. Health and marketing: The emergence of a new field of research. International Journal of Research in Marketing 25 (4): 229–233.CrossRef
Zurück zum Zitat Stremersch, S., V. Landsman, and S. Venkataraman. 2013. The relationship between DTCA, drug requests, and prescriptions: Uncovering variation in specialty and space. Marketing Science 32 (1): 89–110.CrossRef Stremersch, S., V. Landsman, and S. Venkataraman. 2013. The relationship between DTCA, drug requests, and prescriptions: Uncovering variation in specialty and space. Marketing Science 32 (1): 89–110.CrossRef
Zurück zum Zitat Stremersch, S., and A. Lemmens. 2009. Sales growth of new pharmaceuticals across the globe: The role of regulatory regimes. Marketing Science 28 (4): 690–708.CrossRef Stremersch, S., and A. Lemmens. 2009. Sales growth of new pharmaceuticals across the globe: The role of regulatory regimes. Marketing Science 28 (4): 690–708.CrossRef
Zurück zum Zitat Stremersch, S., and W. Van Dyck. 2009. Marketing of the life sciences: A new framework and research agenda for a nascent field. Journal of Marketing 73 (4): 4–30.CrossRef Stremersch, S., and W. Van Dyck. 2009. Marketing of the life sciences: A new framework and research agenda for a nascent field. Journal of Marketing 73 (4): 4–30.CrossRef
Zurück zum Zitat The Economist. 2015. Drug pricing in America: Painful Pills. Sep 26. The Economist. 2015. Drug pricing in America: Painful Pills. Sep 26.
Zurück zum Zitat Thirumalai, S., and K. Sinha. 2011. Product recalls in the medical device industry: An empirical exploration of the sources and financial consequences. Management Science 57 (2): 376–392.CrossRef Thirumalai, S., and K. Sinha. 2011. Product recalls in the medical device industry: An empirical exploration of the sources and financial consequences. Management Science 57 (2): 376–392.CrossRef
Zurück zum Zitat Vakratsas, D., and C. Kolsarici. 2008. A dual-market diffusion model for a new prescription pharmaceutical. International Journal of Research in Marketing 25 (4): 282–293.CrossRef Vakratsas, D., and C. Kolsarici. 2008. A dual-market diffusion model for a new prescription pharmaceutical. International Journal of Research in Marketing 25 (4): 282–293.CrossRef
Zurück zum Zitat Vakratsas, D., and C. Kolsarici. 2014. How DTCA influences prescription pharmaceutical markets. In Innovation and marketing in the pharmaceutical industry: Emerging practices, research, and policies, ed. M. Ding, J. Eliashberg, and S. Stremersch. New York: Springer. Vakratsas, D., and C. Kolsarici. 2014. How DTCA influences prescription pharmaceutical markets. In Innovation and marketing in the pharmaceutical industry: Emerging practices, research, and policies, ed. M. Ding, J. Eliashberg, and S. Stremersch. New York: Springer.
Zurück zum Zitat Valente, T.W. 1996. Social network thresholds in the diffusion of innovations. Social Networks 18 (1): 69–89.CrossRef Valente, T.W. 1996. Social network thresholds in the diffusion of innovations. Social Networks 18 (1): 69–89.CrossRef
Zurück zum Zitat Van den Bulte, C. 2000. New product diffusion acceleration: Measurement and analysis. Marketing Science 19 (4): 366–380.CrossRef Van den Bulte, C. 2000. New product diffusion acceleration: Measurement and analysis. Marketing Science 19 (4): 366–380.CrossRef
Zurück zum Zitat Van den Bulte, C., and G. Lilien. 2001. Medical innovation revisited: Social contagion versus marketing effort. American Journal of Sociology 106 (5): 1409–1435.CrossRef Van den Bulte, C., and G. Lilien. 2001. Medical innovation revisited: Social contagion versus marketing effort. American Journal of Sociology 106 (5): 1409–1435.CrossRef
Zurück zum Zitat Van den Bulte, C., and S. Stremersch. 2004. Social contagion and income heterogeneity in new product diffusion: A meta-analytic test. Marketing Science 23 (4): 530–544.CrossRef Van den Bulte, C., and S. Stremersch. 2004. Social contagion and income heterogeneity in new product diffusion: A meta-analytic test. Marketing Science 23 (4): 530–544.CrossRef
Zurück zum Zitat Venkataraman, S., and S. Stremersch. 2007. The debate on influencing doctors’ decisions: Are drug characteristics the missing link? Management Science 53 (11): 1688–1701.CrossRef Venkataraman, S., and S. Stremersch. 2007. The debate on influencing doctors’ decisions: Are drug characteristics the missing link? Management Science 53 (11): 1688–1701.CrossRef
Zurück zum Zitat Verniers, I., S. Stremersch, and C. Croux. 2011. The global entry of new pharmaceuticals: A joint investigation of launch window and price. International Journal of Research in Marketing 28 (4): 295–308.CrossRef Verniers, I., S. Stremersch, and C. Croux. 2011. The global entry of new pharmaceuticals: A joint investigation of launch window and price. International Journal of Research in Marketing 28 (4): 295–308.CrossRef
Zurück zum Zitat Williams, G., G. Rodin, R. Ryan, W. Grolnick, and E. Deci. 1998. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychology 17 (3): 269–276.CrossRef Williams, G., G. Rodin, R. Ryan, W. Grolnick, and E. Deci. 1998. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychology 17 (3): 269–276.CrossRef
Zurück zum Zitat Wilkes, M., R. Bell, and R. Kravitz. 2000. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Affairs 19 (2): 110–128.CrossRef Wilkes, M., R. Bell, and R. Kravitz. 2000. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Affairs 19 (2): 110–128.CrossRef
Zurück zum Zitat Windmeijer, F., E. De Laat, R. Douven, and E. Mot. 2006. Pharmaceutical promotion and GP prescription behavior. Health Economics 15 (1): 5–18.CrossRef Windmeijer, F., E. De Laat, R. Douven, and E. Mot. 2006. Pharmaceutical promotion and GP prescription behavior. Health Economics 15 (1): 5–18.CrossRef
Zurück zum Zitat Wosinska, M. (2002) Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. Working Paper Harvard Business School, 03-058. Wosinska, M. (2002) Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. Working Paper Harvard Business School, 03-058.
Zurück zum Zitat Wosinska, M. 2005. Direct-to-consumer advertising and drug therapy compliance. Journal of Marketing Research 42 (3): 323–332.CrossRef Wosinska, M. 2005. Direct-to-consumer advertising and drug therapy compliance. Journal of Marketing Research 42 (3): 323–332.CrossRef
Zurück zum Zitat Wuyts, S., S. Dutta, and S. Stremersch. 2004. Portfolios of interfirm agreements in technology-intensive markets: Consequences for innovation and profitability. Journal of Marketing 68 (2): 88–100.CrossRef Wuyts, S., S. Dutta, and S. Stremersch. 2004. Portfolios of interfirm agreements in technology-intensive markets: Consequences for innovation and profitability. Journal of Marketing 68 (2): 88–100.CrossRef
Metadaten
Titel
Marketing Models for the Life Sciences Industry
verfasst von
Vardan Avagyan
Vardit Landsman
Stefan Stremersch
Copyright-Jahr
2017
DOI
https://doi.org/10.1007/978-3-319-56941-3_13

Premium Partner